The National Institute of Health (NIH)’s follow-up study on participants that were part of an eye supplement study has revealed that elevated lung cancer risks linked with the supplement still exist around 30 years later.
The study found that though the current Age-Related Eye Disease supplement (AREDS) is effective at slowing the progression macular degeneration, with no increased risk of lung cancer, participants who consumed the original supplement as part of the first trial still carried elevated risk of lung cancer linked to the ingredient in the original formula, despite having switched to the newer and safer formula for many years….